Evidence map›Paper›PMID 29440633›Full record

ArticleCell death & disease2018

KRAS induces lung tumorigenesis through microRNAs modulation.

Lei Shi, Justin Middleton, Young-Jun Jeon, Peter Magee, Dario Veneziano, Alessandro Laganà, Hui-Sun Leong, Sudhakar Sahoo, Matteo Fassan, Richard Booton and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors.Medical oncology (Northwood, London, England) · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Lei ShiTranscriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.
Justin MiddletonDepartment of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Young-Jun JeonDepartment of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Peter MageeTranscriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.
Dario VenezianoDepartment of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Alessandro LaganàDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, 10029, USA.
Hui-Sun LeongRNA Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.
Sudhakar SahooRNA Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.
Matteo FassanDepartment of Medicine, Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy.ORCID 0000-0001-6515-5482
Richard BootonManchester Thoracic Oncology Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, M23 9LT, UK.
Rajesh ShahDepartment of Thoracic Surgery, University Hospital of South Manchester, Southmoor Road, Wythenshawe, M23 9LT, UK.
Philip A J CrosbieCancer Research UK Lung Cancer Centre of Excellence, Manchester and University College London, London, UK.
Michela GarofaloTranscriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK. michela.garofalo@cruk.manchester.ac.uk.
Cancer Genetics (United States) · USCancer Research UK · GBUniversity of Manchester · GBWythenshawe Hospital · GBIcahn School of Medicine at Mount Sinai · USUniversity of Padua · IT

Funding

Cancer Research UK 19995Cancer Research UK 20465Cancer Research UK C5759/A20465Cancer Research UK C5759/A20971
6 · The paper itself

Abstract

Oncogenic KRAS induces tumor onset and development by modulating gene expression via different molecular mechanisms. MicroRNAs (miRNAs) are small non-coding RNAs that have been established as main players in tumorigenesis. By overexpressing wild type or mutant KRAS (KRAS

Indexed as

AnimalsCarcinogenesisHumansLung NeoplasmsMiceMicroRNAsProto-Oncogene Proteins p21(ras)MicroRNAsProto-Oncogene Proteins p21(ras)

Identifiers

PMID29440633
PMCPMC5833396
OpenAlexW2789289999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.